The outlook of companies tied to the drug's past presents a intricate investment landscape. While the initial surge generated substantial returns , generic copies have significantly eroded market share . Investing in connected pharmaceutical businesses now requires a careful assessment of proprietary rights , evolving medical shifts , and the prosp